{"nct_id":"NCT07154706","title":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-08-21","start_date_type":"ACTUAL","primary_completion_date":"2030-08-30","primary_completion_date_type":"ESTIMATED","completion_date":"2033-08-30","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["NUVB"]}